(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
4 September 2014 (04.09.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/134255 A3

(51) International Patent Classification:
C12N 15/113 (2010.01) *A61K 31/7088* (2006.01)

(21) International Application Number:
PCT/US2014/018873

(22) International Filing Date:
27 February 2014 (27.02.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/770,713 28 February 2013 (28.02.2013) US

(71) Applicant: **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and
(71) Applicants : **BETTENCOURT, Brian** [US/US]; Alnylam Pharmaceuticals, Inc., 300 Third Street, Cambridge, Massachusetts 02142 (US). **GANESH, Shanthi** [US/US]; Novartis Pharmaceuticals Corporation, One Health Plaza, East Hanover, New Jersey 07936 (US). **GEORGE, Elizabeth** [US/US]; Novartis Institutes of BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **HUESKEN, Dieter** [DE/CH]; Novartis Pharma AG, Postfach, CH-4002 Basel (CH). **MILSTEIN, Stuart** [US/US]; Alnylam Pharmaceuticals, Inc., 300 Third Street, Cambridge, Massachusetts 02142 (US). **SOLOMON, Jonathan** [US/US]; Novartis Institutes of BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **THOMAS, Emily** [US/US]; Novartis Institutes of BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **TOUDJARSKA, Ivanka** [US/US]; Alnylam Pharmaceuticals, Inc., 300 Third Street, Cambridge, Massachusetts 02142 (US). **TULLAI, Jennifer** [US/US]; Novartis Institutes of BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US). **WEILER, Jan** [US/US]; Novartis Institutes of BioMedical Research, Inc., 250 Massachusetts Avenue, Cambridge, Massachusetts 02139 (US).

(74) Common Representative: **NOVARTIS AG**; Lichtstrasse 35, CH-4056 Basel (CH).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

— *with international search report (Art. 21(3))*

— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*

(88) Date of publication of the international search report:
31 December 2014

(54) Title: ORGANIC COMPOSITIONS TO TREAT EPAS1-RELATED DISEASES

(57) Abstract: The present disclosure relates to methods of treating EPAS1-related diseases such as cancer, metastases, astrocytoma, bladder cancer, breast cancer, chondrosarcoma, colorectal carcinoma, gastric carcinoma, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, lung adenocarcinoma, neuroblastoma, non-small cell lung cancer, melanoma, multiple myeloma, ovarian cancer, rectal cancer, renal cancer, clear cell renal cell carcinoma (and metastases of this and other cancers), gingivitis, psoriasis, Kaposi's sarcoma-associated herpesvirus, preemclampsia, inflammation, chronic inflammation, neovascular diseases, and rheumatoid arthritis, using a therapeutically effective amount of a RNAi agent to EPAS1.

WO 2014/134255 A3